Eli Lilly and Company

Grove Biopharma is a biotechnology company specializing in materials science solutions for peptide therapeutics. It focuses on discovering and developing novel 'protein-like polymers' to address significant unmet medical needs in chronic inflammatory and neurodegenerative diseases.

Heyuan Medical Devices serves as an enterprise service provider, offering specialized medical equipment and support solutions tailored to the needs of healthcare institutions and organizations

Solu Therapeutics is a precision medicine company developing therapeutics focused on eliminating disease-driving cells. Its platform combines selective small-molecule binders with proprietary antibodies to create bifunctional therapeutics, targeting inflammatory and autoimmune diseases.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

Fine Vision is a company with R&D facilities in Nanjing and Wuhan that focuses on femtosecond laser application research in the fields of ocular surgery and biomaterial processing. The entire femtosecond laser corneal refractive surgery equipment, its first commercially available item, was developed by the university's Wuhan Optoelectronics National Research Center under the Huazhong Technology Technology transition.

Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.

Verdiva Bio is a biopharmaceutical company specializing in the development of innovative therapies for patients with obesity and cardiometabolic disorders. The company focuses on creating more patient-friendly treatment options by targeting gut-brain biology, with a pipeline centered around multiple amylin molecules. This approach aims to enhance efficacy, improve tolerability, and facilitate healthier weight loss for individuals facing these health challenges.

Orbis Medicines is a company that develops a macrocyclic chemistry and computational platform for oral macrocycle drug discovery. The platform generates macrocycle candidates, nCycles, optimized for oral bioavailability to advance therapeutics that historically faced development hurdles. Its pipeline centers on nCycle candidates targeting validated biologic targets that are typically addressed by injectable drugs, with the goal of enabling oral delivery of such therapies. The platform combines chemistry and computational methods to accelerate drug discovery toward challenging targets in unmet-need indications, supporting therapeutics designed to improve patient outcomes.

Syneron was founded by Sinovation Ventures and is dedicated to using artificial intelligence and biotechnology to address two significant global challenges: the efficient development of novel biological therapies and the low-carbon manufacture of biochemicals.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

Founded in 2021, Arda Therapeutics is a biotechnology company based in the San Francisco Bay Area. It specializes in developing transformative therapeutics to eliminate pathogenic cells that drive chronic diseases and aging.

NanoSyrinx is a biotechnology company focused on developing a novel biologics drug delivery platform that targets therapeutic proteins and peptides to the cytosol of cells. Through synthetic biology, the company seeks to transport payloads directly into cell interiors, aiming to improve the efficacy, safety, and cost-effectiveness of treatments. The platform is designed to serve the biopharmaceutical sector by enabling targeted delivery of biologics to intracellular targets, with potential to enhance treatment outcomes across multiple indications.

Superluminal Medicines is a biotechnology company specializing in generative biology and chemistry. It employs a unique platform that combines deep biological and chemical expertise, machine learning, and proprietary big data infrastructure to rapidly generate candidate-ready compounds for drug discovery and development. By integrating high-throughput experimental data with advanced algorithms, the company aims to accelerate the identification and optimization of novel drug candidates, improving efficiency and success rates in small molecule drug development compared to traditional methods.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

RetiSpec is developing a non-invasive eye scanner for the early detection of Alzheimer’s Disease pathology years before symptoms occur. This enables clinicians to intervene with emerging therapeutics at an earlier stage when there's a chance of impacting the disease.

Rona Therapeutics is an innovative RNA therapeutics platform focused on the discovery, development, and commercialization of modular and programmable RNA medicines. The company specializes in oligonucleotide therapies, RNA editing, and polymeric molecules, aiming to create transformative RNA therapies that can significantly impact disease treatment across various therapeutic areas. Rona Therapeutics is committed to developing proprietary technologies that enhance the specificity, stability, and longevity of therapeutic effects. To support its mission, the company is establishing state-of-the-art facilities to advance nucleic acid synthesis, delivery platforms, and RNA biology. Through its efforts, Rona Therapeutics seeks to improve patient health outcomes and foster an environment conducive to innovation and excellence in RNA medicine.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.

Zephyr AI is a healthcare technology company focused on transforming drug discovery and precision medicine. By leveraging large complex datasets and proprietary algorithms, Zephyr AI aims to redefine drug development and streamline clinical trials. The company collaborates with leading health systems, health insurance plans, and biotechnology innovators to enhance healthcare quality, improve patient outcomes, and reduce costs. Through its innovative approach, Zephyr AI seeks to address challenges in disease treatment and clinical decision support, ultimately contributing to advancements in the healthcare sector.

FireFly Bio is a biotechnology company focused on developing innovative therapies for cancer through its proprietary platform centered on Degrader Antibody Conjugates (DACs). This technology merges the advantages of traditional antibody-drug conjugates (ADCs) with selective protein degradation, allowing for the targeted delivery of therapeutic agents to specific tissues. By leveraging advanced bioconjugate technologies, FireFly Bio aims to create highly specific and effective treatments that enhance patient outcomes. The company's approach emphasizes precision in medicine, seeking to improve the potency and efficacy of cancer therapies.

Synnovation Therapeutics is a precision oncology company that specializes in the development of small molecule therapies aimed at addressing key driver mechanisms in cancer. The company is committed to discovering and advancing therapeutics that enhance the quality of life for cancer patients. By leveraging its expertise in medicinal chemistry, cancer biology, and patient-focused precision medicine, Synnovation Therapeutics cultivates a diverse pipeline of innovative targeted therapies. Its objective is to efficiently progress these agents into clinical trials, ultimately transforming the standard of care in cancer treatment and improving patient outcomes.

ViaNautis specializes in the development of innovative medications that effectively cross biological barriers, including the blood-brain barrier. The company employs its proprietary PolyNaut technology, a versatile nano-engineered polymer system designed for intracellular delivery. This technology allows for the encapsulation of various therapeutic modalities into polymer nanovesicles, which can selectively target different tissues and cell types. By facilitating the penetration of these barriers, ViaNautis enhances the therapeutic efficacy of the encapsulated molecules, providing significant benefits in medication delivery and treatment outcomes. Collaborating with multiple partners, the company aims to revolutionize how medications are developed and delivered, particularly in addressing challenging medical conditions.

OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders such as diabetes, dyslipidemia, and lipodystrophies. It aims to restore energy homeostasis by targeting pathways relevant to maintaining energy balance.

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Enchannel Medical is a global innovation platform specializing in electrophysiology, particularly in the treatment of atrial fibrillation. The company has developed an integrated solution that combines advanced three-dimensional mapping with pulsed field ablation technology. Their unique four-dimensional mapping system leverages both magnetoelectric positioning contact and non-contact mapping technologies, allowing for real-time visualization of arrhythmia mechanisms during electrophysiological procedures. This innovation aims to enhance the safety and efficacy of cardiac arrhythmia surgeries, providing physicians with refined tools for better patient outcomes in the management of atrial fibrillation.

Crossbow Therapeutics is a biotechnology company focused on developing innovative cancer treatments. The company engineers antibodies to mimic T-cells, which are essential components of the immune system, aiming to enhance the quality of life for cancer patients. Their next-generation immunotherapies are designed to target previously unreachable cancer cell proteins with high precision, offering an efficient and selective approach to cancer treatment. By unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies, Crossbow Therapeutics seeks to dramatically expand the capabilities of antibody therapy across various cancer types, ultimately improving patient outcomes.

Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.

Trans Solutions Research and Resource Center empowers transgender and gender communities.

Langlai Technology is a clinical-stage innovative drug research and development company. Adhering to the dual-drive strategy of synchronously improving the R&D pipeline and platform construction, it has built a full-process new drug R&D process from concept verification, candidate compound screening, preclinical druggability development to clinical research. system.

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. Its mission is to provide safe, effective, evidence-based, and affordable therapies for treating life-threatening complications of pregnancy.

DiogenX is a French biotechnology company founded in 2019, focused on developing therapeutic solutions for diabetic patients. It specializes in pancreatic beta-cell modulators for treating Type 1 and Type 2 diabetes by regenerating insulin-producing cells.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

Switch Therapeutics is a biotechnology company founded in 2020 and based in San Francisco, California. The company focuses on revolutionizing RNA interference (RNAi) therapies by developing biomarker-gated genetic medicines. These innovative therapies utilize nucleic acid nanotechnology and RNAi science to target a variety of diseases, particularly those affecting the central nervous system and other systemic conditions with significant unmet medical needs. Switch Therapeutics aims to provide healthcare providers with RNA molecules and therapies that can be activated selectively in specific cells, enhancing the precision of treatments for central nervous system diseases.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

LavaMed is a Chinese manufacturer of medical devices. It specializes in minimally invasive surgical instruments, diagnostic equipment, and customized medical technology services, aiming to enhance clinical accuracy and patient safety for improved healthcare outcomes.

SonoThera is a biotechnology company focused on developing innovative genetic therapies using ultrasound technology. The company's mission is to create non-viral genetic medicines that address the root causes of human diseases. SonoThera specializes in ultrasound-guided nonviral gene therapy, aiming to provide effective treatments for conditions that currently have suboptimal or no available treatments. By leveraging this approach, SonoThera seeks to enhance the health and quality of life for millions of people worldwide.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Strand Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in genetically programming mRNA to deliver innovative therapies aimed at enhancing patient outcomes. Founded in 2017, the company develops mRNA programming technology that allows for precise control over the location, timing, and intensity of therapeutic protein expression within the body. By employing mRNA-encoded logic circuits, Strand Therapeutics can achieve cell-type specific expression by detecting unique miRNA signatures and modulating protein dosage in response to externally administered small molecules. The company focuses on creating gene therapies powered by synthetic biology, including immunotherapies designed to enable cells to produce target cancer-killing proteins, thereby strengthening the body's immune response against cancer.

Rezo Therapeutics is a biotechnology company that focuses on pioneering the integrated mapping of disease networks to develop precision therapeutics. Utilizing its proprietary Sequence to Systems to Drugs (SSD) platform, Rezo combines proteomics, genetics, structural biology, chemistry, and bioinformatics to create comprehensive maps of molecular disease networks. This innovative approach enables oncologists and researchers to identify novel targets and therapies with greater clarity and precision than traditional drug discovery methods. Initially concentrating on oncology, Rezo Therapeutics plans to expand its therapeutic focus through collaborations and partnerships, aiming to address a wide range of diseases.

Lupeng Pharmaceutical is a clinical-stage company specializing in the drug discovery and development of innovative therapies, particularly for cancer treatment. The company is actively engaged in research and development aimed at producing novel molecular drugs that address a variety of serious health conditions, including tumors and hepatitis B. Through its focus on advancing innovative treatments, Lupeng Pharmaceutical aims to provide effective solutions for combating cancer and other significant diseases.

Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

Photys Therapeutics is a biopharmaceutical company focused on developing bifunctional small molecules that provide precise control over protein post-translational modifications. This innovative platform allows for the restoration of protein function, repair of cellular signaling pathways, and enhancement of the body's natural disease-fighting abilities. Co-founded by prominent chemist Amit Choudhary from the Broad Institute and the Longwood Fund, Photys is supported by a scientific advisory board that includes renowned experts from institutions such as MIT, Salk Institute, and Berkeley. The company's unique approach aims to advance therapeutic options in the healthcare industry, particularly by targeting kinases and potentially phosphatases, to address various diseases effectively.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

Neukio Biotherapeutics is a biopharmaceutical company dedicated to the development of immune cell therapies aimed at treating cancer. The company specializes in the research, development, and industrialization of allogenic immune cell drugs, particularly focusing on iPSC-CAR-NK cell products. By leveraging a combination of in-house innovation and strategic collaborations with leading partners, Neukio Biotherapeutics aims to provide effective therapeutic options for cancer patients globally. Their commitment to advancing oncology treatments positions them as a significant player in the field of immunotherapy.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

Rona Therapeutics is an innovative RNA therapeutics platform focused on the discovery, development, and commercialization of modular and programmable RNA medicines. The company specializes in oligonucleotide therapies, RNA editing, and polymeric molecules, aiming to create transformative RNA therapies that can significantly impact disease treatment across various therapeutic areas. Rona Therapeutics is committed to developing proprietary technologies that enhance the specificity, stability, and longevity of therapeutic effects. To support its mission, the company is establishing state-of-the-art facilities to advance nucleic acid synthesis, delivery platforms, and RNA biology. Through its efforts, Rona Therapeutics seeks to improve patient health outcomes and foster an environment conducive to innovation and excellence in RNA medicine.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

ArriVent is a biopharmaceutical company focused on developing innovative medicines to treat currently untreatable cancers. It aims to advance its lead candidate, furmonertinib, and other novel therapeutics like next-generation antibody-drug conjugates through clinical development and commercialization, initially targeting solid tumors.

Founded in 2018, Fountain Therapeutics develops cellular model-based therapeutics targeting age-related diseases. It employs an AI-driven platform for identifying novel targets and potential treatments.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

GenEdit Inc., established in 2016 and headquartered in Berkeley, California, specializes in developing innovative genome editing tools. The company's core technology is CRISPR/Cas9, which enables precise therapeutic gene editing. GenEdit has further advanced this field by creating the NanoGalaxy™ platform, a proprietary non-viral delivery system that efficiently transports CRISPR/Cas9 to target tissues, overcoming previous delivery challenges. This platform systematically screens a library of nanoparticles to ensure safer and more effective delivery, making therapeutic gene editing easier, faster, and more accurate than traditional methods. GenEdit's ultimate goal is to facilitate the cure of previously incurable genetic diseases by providing physicians with powerful tools for gene therapy.

Iterative Scopes, Inc. is a Boston-based company established in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and life sciences professionals within the colorectal cancer and inflammatory bowel disease sectors. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical areas of healthcare.

Lupeng Pharmaceutical is a clinical-stage company specializing in the drug discovery and development of innovative therapies, particularly for cancer treatment. The company is actively engaged in research and development aimed at producing novel molecular drugs that address a variety of serious health conditions, including tumors and hepatitis B. Through its focus on advancing innovative treatments, Lupeng Pharmaceutical aims to provide effective solutions for combating cancer and other significant diseases.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

ArriVent is a biopharmaceutical company focused on developing innovative medicines to treat currently untreatable cancers. It aims to advance its lead candidate, furmonertinib, and other novel therapeutics like next-generation antibody-drug conjugates through clinical development and commercialization, initially targeting solid tumors.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Scivita Medical is a high-tech enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging technologies and high-performance materials. The company focuses on precision manufacturing for minimally invasive medical procedures and is recognized for its advancements in endoscopy technology. Scivita Medical offers a range of products that include flexible and rigid endoscopes, featuring innovations such as ultra-high-definition visualization, 3D imaging, and specialized light visualization techniques, including fluorescence. Its portfolio encompasses various medical devices, including 4K medical endoscope camera systems, integrated endoscope systems, and single-use electronic instruments like hysteroscopes, bladder pyeloscopes, and bronchoscopes. These products are designed to provide healthcare professionals with efficient tools for diagnosis and treatment, enhancing the capabilities of modern endoscopic procedures.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology. The firm is focused on developing innovative antibody-drug conjugate therapies targeting CD46, aimed at treating late-stage multiple myeloma and prostate cancer, among other indications. Utilizing its platform, Fortis Therapeutics prepares antibody-drug conjugates that are designed to effectively address both adenocarcinoma and neuroendocrine cancers, providing oncologists with new therapeutic options for challenging late-stage malignancies.

Kelun Biotech is a biopharmaceutical company dedicated to researching, developing, manufacturing, and commercializing innovative drugs. With over a decade of experience, they specialize in antibody-drug conjugates (ADCs) to address prevalent or hard-to-treat cancers and other diseases worldwide.

NovoCodex is involved in the research, development, and manufacture of biological products. Its mission is to provide cutting-edge technology to meet clinical needs. In Binhai New City Science and Technology Park, the company has established a biopharmaceutical laboratory with experience and capabilities in genetic engineering construction, cell culture, toxin synthesis, ADC coupling, preparation filling, preclinical research, and clinical research.

Indianapolis Cultural Trail operates as a 501c3 nonprofit organization that engages in urban trails and linear parks and is committed to a sustainable funding model that ensures accessible connections for future generations.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic (IVD) company based in Suzhou, China, with a research and development office in Singapore. Founded in 2019, the company specializes in developing advanced diagnostic platforms for the detection of infectious diseases, cancer, and chronic diseases. Its technology offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Virtue Diagnostics aims to enhance diagnostic capabilities and improve patient outcomes through its innovative solutions.

Faze Medicines is a biotechnology company focused on developing small molecule therapies that target biomolecular condensates to address the underlying biology of disease. It uses screening and proteomics to define condensate interaction networks and identify therapeutic candidates aimed at cellular mechanisms implicated in conditions such as amyotrophic lateral sclerosis and myotonic dystrophy type 1, with research extending to other diseases including frontotemporal dementia. Founded in 2020 and based in Cambridge, Massachusetts.

SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.

Eluminex Biosciences is engaged in the research, development, and commercialization of innovative therapies aimed at addressing unmet medical needs in ocular health. The company focuses on ophthalmology and tissue regeneration, leveraging recombinant human collagen to develop therapeutic solutions. Its pipeline includes treatments designed to slow and mitigate the effects of aging and overuse on vision, ultimately enabling healthcare providers to offer improved care to their patients. Through its commitment to advancing the field of ophthalmology, Eluminex Biosciences seeks to enhance diagnostic and therapeutic options for ocular illnesses.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Woodstock, Georgia, focused on developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, dermatology, animal health, eye care, and oral care. With over 100 products commercialized in 33 countries, Sonoma addresses unmet medical needs through its innovative therapies aimed at chronic skin conditions. Key offerings include Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product for dermatoses; Celacyn gel for scar management; and SebuDerm for seborrheic dermatitis. Additionally, the company provides Microcyn, which targets various pathogens to promote wound healing, and Acuicyn, designed for eye care. Sonoma Pharmaceuticals was formerly known as Oculus Innovative Sciences, Inc. and has been incorporated since 1999. Its commitment to improving patient care and reducing healthcare costs is reflected in its diverse product portfolio that caters to both prescription and non-prescription needs.

Nido Biosciences is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing precision medicines and small-molecule therapeutics for severe neurological and neuromuscular diseases. It employs a functional genomics platform using human cell lines and tailored screens to identify therapeutic targets driven by human genetics, with the aim of addressing the underlying biology of disease and restoring healthy cell function through targeted interventions.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Legend Biotech is a clinical-stage biopharmaceutical company focused on discovering and developing novel cell therapies for oncology and other indications. Its lead candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T therapy for multiple myeloma, evaluated in various trials including earlier-line settings and comparisons with standard therapies in Revlimid-refractory disease. The company also has a broad pipeline of autologous and allogeneic CAR-T and related immunotherapies targeting solid tumors and hematologic cancers, including investigations into CD20-directed allogeneic CAR-T for non-Hodgkin lymphoma in China as an investigator-initiated Phase 1 study, as well as early preclinical and clinical programs for additional cancers and infectious diseases. Legend Biotech was founded in 2014 and is based in Somerset, New Jersey; it is a subsidiary of Genscript Biotech Corporation.

Yantai Rongchang Pharmaceutical Co., Ltd. is a pharmaceutical company based in Yantai, China, founded in 1993. The company engages in the research and development, production, and distribution of modern Chinese medicine and biological drugs. Over the years, Rongchang Pharmaceutical has evolved into a comprehensive enterprise that combines various aspects of the pharmaceutical industry, focusing on innovation and the development of effective healthcare solutions.

DTx Pharma, LLC is a biotechnology company headquartered in San Diego, California, specializing in the development and commercialization of fatty acid-conjugated peptide therapeutics. Founded in 2017, the company focuses on delivering RNA-based medicines to treat patients with rare and chronic diseases, including retinitis pigmentosa, Duchenne muscular dystrophy, and various central nervous system disorders. DTx Pharma's innovative delivery technology addresses challenges faced by previous-generation platforms, such as poor pharmacokinetics and limited cellular uptake, thereby enhancing the efficiency of nucleic acid drug delivery across diverse tissues and cell types. The company aims to establish RNA therapeutics as a leading option for personalized treatment in multiple therapeutic areas.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Ionova Life Science Co., Ltd. is a biotechnology company founded in 2016 and based in Shenzhen, China, with additional offices in Hong Kong, Macao, and the Greater Bay Area. The company specializes in the discovery and development of novel medicines for cancer treatment, focusing on oncology, including immune-oncology and targeted delivery approaches. Ionova is dedicated to creating innovative tumor-targeted drugs and immunomodulatory therapies for cancer and related diseases, employing its proprietary discovery platform to advance its research and product development initiatives.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Passage Bio is a gene therapy company dedicated to developing transformative treatments for rare, monogenic central nervous system disorders. It has an integrated pipeline of five AAV-delivered therapeutics and collaborates with the University of Pennsylvania's Gene Therapy Program for preclinical work.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Elpiscience Biopharmaceuticals Co., Ltd. is a clinical-stage biopharmaceutical company based in Pudong, China, with an additional office in Suzhou. It specializes in developing next-generation immunotherapies aimed at treating cancer. The company boasts a robust pipeline of innovative molecules that target a wide array of challenges in immuno-oncology. Founded by experienced leaders and scientists in the biopharmaceutical field, Elpiscience is committed to advancing at least one innovative molecule into clinical trials each year, with the goal of improving treatment options for cancer patients globally.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.

Rimidi Inc. is a healthcare technology company focused on improving diabetes management for patients and healthcare providers. Founded in 2011 and based in Atlanta, Georgia, Rimidi develops a cloud-based software solution called DIABETES+ME, which integrates patient-generated health data from connected devices with clinical data to identify gaps in diabetes care. This platform allows physicians to monitor patients remotely, providing insights that facilitate timely interventions and treatment adjustments. By promoting effective communication and data-driven decision-making, Rimidi aims to enhance the overall management of diabetes, addressing a critical issue in healthcare. The company was formerly known as Rimidi Diabetes, Inc. and rebranded in July 2018.

Ansun Biopharma is a clinical-stage biopharmaceutical company based in San Diego that develops host-directed anti-viral therapies to prevent and treat life-threatening respiratory infections. The company focuses on therapies targeting the host rather than the virus, aiming to overcome viral mutation and immune evasion. Its pipeline includes Fludase, candidate for prophylaxis and treatment of influenza and parainfluenza infections, and Viradin, an intravenous therapy for sepsis, septic shock, and certain viral hemorrhagic fevers. It also advances TOSAP formulation technology to create microspheres and nanospheres for drug delivery. Through these programs, Ansun Biopharma seeks to provide therapies for severe viral diseases where traditional antivirals face limitations.

Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, that specializes in the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, Tmunity focuses on harnessing the potential of T cells through novel technologies, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg). The company has developed advanced platforms that allow for precise control over T cell activation and direction in vivo, as well as proprietary methods for activating, expanding, and genetically engineering T cells sourced from peripheral blood, cord blood, and tumors. Tmunity aims to advance personalized next-generation immunotherapies and has a team of experts with extensive experience in T-cell biology and clinical development, enhancing its capability to conduct safe and effective clinical trials. Its robust manufacturing platform supports multi-center clinical studies across various therapeutic areas, positioning Tmunity at the forefront of immunotherapy innovation.

Founded in 2017, Terns Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing molecularly targeted, oral small-molecule drugs for treating cancer and liver diseases. Headquartered in Foster City, California with offices in Shanghai, China, the company focuses on advancing its pipeline of drugs optimized against clinically validated targets.

Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing functional cures for patients with chronic diseases. Founded in 2015, the company aims to create immune-protected, engineered human cells that restore normal physiological functions without the risk of fibrosis or immune rejection. Its lead product candidate, SIG-001, is currently in Phase I/II clinical trials for preventing bleeding episodes in patients with moderate to severe Hemophilia A. Additionally, Sigilon is advancing other candidates, including SIG-005, which targets non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells for treating type 1 diabetes. The company's innovative Shielded Living Therapeutics platform leverages advances in cell engineering and proprietary biocompatible materials to offer stable and durable therapeutic solutions for a variety of chronic conditions.

Singlera Genomics Inc. is a biotechnology company that specializes in genetic testing and molecular diagnostic technologies. Founded in 2014 and headquartered in La Jolla, California, with additional operations in Shanghai, China, Singlera develops a methylation detection platform designed for early cancer diagnosis and prevention. The company offers a range of services, including tumor diagnosis, personalized treatment, non-invasive prenatal diagnosis, and pre-implantation genetic screening. Additionally, Singlera is focused on advancing precision medicine, aiming to provide patients with early, accurate, and informative diagnostic solutions to improve healthcare outcomes.

Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, that specializes in the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, Tmunity focuses on harnessing the potential of T cells through novel technologies, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg). The company has developed advanced platforms that allow for precise control over T cell activation and direction in vivo, as well as proprietary methods for activating, expanding, and genetically engineering T cells sourced from peripheral blood, cord blood, and tumors. Tmunity aims to advance personalized next-generation immunotherapies and has a team of experts with extensive experience in T-cell biology and clinical development, enhancing its capability to conduct safe and effective clinical trials. Its robust manufacturing platform supports multi-center clinical studies across various therapeutic areas, positioning Tmunity at the forefront of immunotherapy innovation.